GlassScriptPhysician profile
Richard E Lochamy
NPI 1184615858
$691.17
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.86 · 2020: $115 · 2021: $152 · 2022: $167 · 2023: $71.54 · 2024: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $203.99 | 2022-2024 | Yupelri |
| Lilly USA, LLC | $111.12 | 2019-2021 | |
| Novo Nordisk INC | $65.05 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $54.80 | 2021-2022 | |
| Amgen INC. | $44.08 | 2019-2024 | Otezla, Repatha |
| Eisai INC. | $35.50 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $28.42 | 2019-2020 | |
| Apria Healthcare LLC | $24.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.34 | 2021 | |
| Medtronic, INC. | $19.86 | 2022 | |
| Abbvie INC. | $18.57 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.15 | 2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $17.49 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $13.72 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lochamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.